Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Pacific Biosciences of California, Inc. has 310.81M shares outstanding.

As of June 30, 2026, Pacific Biosciences of California, Inc. maintains a current ratio of 4.92, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2,126.06, indicating conservative leverage, while an interest coverage ratio of -15.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -16.66, reflecting losses generated across the asset base. The company generates approximately 274,699.32 in revenue per employee across its workforce of 507.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.76 indicates how many times Pacific Biosciences of California, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. recorded 723,873.10 in income tax expense. The company reported a pretax loss of -114.28M and -115.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. generated 139.41M in revenue and converted that into -115.00M in net income, yielding earnings per share of -0.38. EBITDA reached -101.01M, while operating income came in at -156.54M.

As of June 30, 2026, Pacific Biosciences of California, Inc. holds 207.33M in cash and equivalents against 618.07M in total debt, resulting in a net debt position of 510.59M. Total book value stands at -29.07M, with working capital of 236.18M providing operational flexibility.

Pacific Biosciences of California, Inc. produced -103.33M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.88M in capital expenditures, free cash flow totaled -114.21M - equivalent to -0.37 per share.

Over the twelve months ended June 30, 2026, Pacific Biosciences of California, Inc. posted a gross margin of 36.38, reflecting its pricing power and cost economics. The operating margin of -112.28 and net profit margin of -82.49 provide insight into operational efficiency.